Our exceptional results for the third quarter demonstrate that Sanofi is on the right path. We delivered remarkable sales growth and our commitment to breakthrough science is bearing fruit as we achieved key regulatory milestones for three of our priority medicines.

Paul Hudson
Chief Executive Officer, Sanofi

**Q3 2022 results**

Company sales and business EPS*

€12,482m
+9.0% (+19.7%)
Q3 2022 company sales**

€2.88
+179% (+32.1%)
Q3 2022 business EPS**

Sales by global business unit

- €4,401m Specialty Care
- €3,315m Vaccines
- €3,495m General Medicines
- €1,271m Consumer Healthcare

Sales by geography

<table>
<thead>
<tr>
<th>Region</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>€6,042m</td>
</tr>
<tr>
<td>Europe</td>
<td>€2,596m</td>
</tr>
<tr>
<td>Rest of the World</td>
<td>€3,844m</td>
</tr>
</tbody>
</table>

Social Impact

Delivering positive impact on communities and the environment

Sanofi is advancing towards its Net Zero target by 2050.

Two carbon offsetting programs launched with EcoAct in Kenya:

- Distributing 18,250 energy-saving biomass cookstoves
  - Avoids approx. 790 kt CO2e
  - Improves health and social conditions of local rural families
- Restoring 500 hectares of mangroves
  - Removes approx. 390 kt CO2e
  - Improves water quality and biodiversity
  - Creates jobs

For further information on Q3 2022 results and definitions of financial indicators, please refer to the press release issued on October 28, 2022 at: www.sanofi.com/en/investors